Check here for the latest on COVID-19 diagnosis and treatment
This study characterizes the prevalence of reverse-transcriptase polymerase chain reaction results positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among patients presenting with influenzalike illness who underwent nasopharyngeal swab testing for influenza and respiratory syncytial virus over 4 days in March 2020.
This study describes findings of novel coronavirus testing on pooled nasopharyngeal and bronchoalveolar lavage samples taken from patients who had negative results by routine respiratory virus testing to see if pooling samples could increase testing throughput and efficiency and facilitate early detection of community COVID-19 transmission.
This study uses data from the National Institutes of Infectious Diseases Japan to compare weekly influenza activity in the 2019/2020 vs the 2014-2019 seasons given mitigation strategies taken in 2020 to limit the spread of COVID-19.
This Medical News article discusses how antibody tests should—and should not—be used during the SARS-CoV-2 pandemic.
This population epidemiology study examines associations between phases of nonpharmaceutical public health interventions (social distancing, centralized quarantine, home confinement, and others) and rates of laboratory-confirmed COVID-19 infection in Wuhan, China, between December 2019 and early March 2020.
This JAMA Patient Page describes the test for coronavirus disease 2019 (COVID-19), current guidelines for determining who should be tested, reasons for slow adoption of testing in the US, and potential drawbacks of alternate tests.
This JAMA Patient Page describes how the novel coronavirus that causes COVID-19 is transmitted and provides measures people can take while grocery shopping, unpacking groceries, and preparing food to minimize the risk of being infected.
This narrative medicine essay emphasizes the undue disease burden carried by minority populations in the COVID-19 pandemic and proposes collection and reporting of data by race/ethnicity and multilingual targeted educational efforts delivered by celebrities or faith leaders as first steps to reduce the imbalance.
This Viewpoint uses the absence of known effective treatment for Ebola virus disease to emphasize the costs of off-label and compassionate drug use during an infectious disease outbreak and the importance of establishing the efficacy and safety of promising drug leads in randomized trials to inform their clinical use.
This Viewpoint discusses the tensions between evaluating treatments (learning) and just treating patients (doing) during the coronavirus disease 2019 (COVID-19) pandemic, and proposes actions the clinical research and practice communities can take to support each other’s imperatives so that both can “learn from doing” in a more integrated patient care approach.
This Viewpoint discusses the legal risks to health care workers and hospital systems from withdrawing or withholding ventilation from COVID-19 patients and cites a Maryland statute that offers legal immunity to clinicians making good faith decisions under emergency conditions as an example for other states to follow.
This Viewpoint discusses the risks to patients and public health posed by the FDA’s politically pressured Emergency Use Authorization (EUA) of chloroquine and hydroxychloroquine for COVID-19 treatment, and proposes principles to follow to ensure new therapies are studied properly and quickly to maximize benefits and minimize risks to patients.
This Viewpoint discusses the long history of racial inequities that cause black populations in US cities to bear a disproportionate burden of COVID-19 illness and mortality and calls for a renewed commitment to eliminating disparities that have been made so starkly visible by the pandemic.
This Viewpoint discusses public health strategies necessary for the US to relax its mitigation strategies—most notably expanded testing, isolation, and contact-tracing in ways that avoid stigmatization of vulnerable populations—and proposes investing returns from a reopened economy to finance testing and public health infrastructure.
This Viewpoint discusses the challenges of accurately modeling the COVID-19 pandemic and reviews principles that will make some models more useful than others, such as use of granular local data when available, regular updating and revision, and specification of uncertainty around estimates.
This Viewpoint discusses potential problems with the US Food and Drug Administration’s emergency use authorization document allowing hydroxychloroquine and chloroquine for the treatment of coronavirus disease 2019 (COVID-19).
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: